Handelen Sutro Biopharma, Inc. - STRO CFD
Toevoegen aan favorieten- Samenvatting
- Historische gegevens
- Evenementen
- Winst- en verliesrekening
- Balans
- Cash Flow
- Eigendom
Handelsvoorwaarden
| Spread | 0.05 | ||||||||
|
Overnight-tarief longpositie
Long position overnight fee
Ga naar platform | -0.025457% | ||||||||
|
Overnight-tarief shortpositie
Short position overnight fee
Ga naar platform | 0.003235% | ||||||||
| Tijd van overnight-tarief | 21:00 (UTC) | ||||||||
| Min. verhandelde hoeveelheid | 1 | ||||||||
| Valuta | USD | ||||||||
| Marge | 20% | ||||||||
| Effectenbeurs | United States of America | ||||||||
| Handelscommissie | 0% |
*Information provided by Capital.com
Sutro Biopharma Inc ESG Risk Ratings
High Medium Low Negligible
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Belangrijkste statistieken
| Prev. Close* | 4.43 |
| Open* | 4.44 |
| 1-Jaarlijkse Verandering* | 5.71% |
| Dagelijks bereik* | 4.43 - 4.69 |
| 52 wekelijks bereik | 3.33-8.72 |
| Weekgemiddelde volume (10 dagen) | 404.69K |
| Gemiddeld volume (3 maanden) | 10.11M |
| Marktkapitalisatie | 269.46M |
| P/E Ratio | -100.00K |
| Uitstaande Aandelen | 60.42M |
| Omzet | 74.55M |
| EPS | -2.38 |
| Dividend (opbrengst %) | N/A |
| Beta | 0.88 |
| Volgende inkomsten datum | Aug 7, 2023 |
Alle gegevens zijn afkomstig van Refinitiv, behalve de gegevens gemarkeerd met een sterretje, die zijn afkomstig van Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Slotkoers | Change | Change (%) | Openingskoers | High | Low |
|---|---|---|---|---|---|---|
| Jun 2, 2023 | 4.69 | 0.41 | 9.58% | 4.28 | 4.70 | 4.28 |
| Jun 1, 2023 | 4.43 | 0.05 | 1.14% | 4.38 | 4.50 | 4.31 |
| May 31, 2023 | 4.48 | -0.10 | -2.18% | 4.58 | 4.68 | 4.41 |
| May 30, 2023 | 4.59 | -0.24 | -4.97% | 4.83 | 4.93 | 4.54 |
| May 26, 2023 | 4.87 | -0.06 | -1.22% | 4.93 | 5.18 | 4.86 |
| May 25, 2023 | 5.04 | 0.06 | 1.20% | 4.98 | 5.10 | 4.96 |
| May 24, 2023 | 5.09 | -0.14 | -2.68% | 5.23 | 5.37 | 5.04 |
| May 23, 2023 | 5.26 | 0.03 | 0.57% | 5.23 | 5.50 | 5.23 |
| May 22, 2023 | 5.28 | -0.01 | -0.19% | 5.29 | 5.57 | 5.27 |
| May 19, 2023 | 5.36 | 0.03 | 0.56% | 5.33 | 5.43 | 5.24 |
| May 18, 2023 | 5.25 | -0.27 | -4.89% | 5.52 | 5.64 | 5.13 |
| May 17, 2023 | 5.71 | 0.07 | 1.24% | 5.64 | 5.74 | 5.46 |
| May 16, 2023 | 5.71 | 0.35 | 6.53% | 5.36 | 6.07 | 5.35 |
| May 15, 2023 | 5.84 | 0.39 | 7.16% | 5.45 | 6.02 | 5.40 |
| May 12, 2023 | 5.62 | 0.43 | 8.29% | 5.19 | 5.65 | 5.19 |
| May 11, 2023 | 5.44 | -0.09 | -1.63% | 5.53 | 5.58 | 5.36 |
| May 10, 2023 | 5.57 | 0.14 | 2.58% | 5.43 | 5.64 | 5.43 |
| May 9, 2023 | 5.47 | 0.37 | 7.25% | 5.10 | 5.54 | 5.10 |
| May 8, 2023 | 5.47 | 0.03 | 0.55% | 5.44 | 5.55 | 5.35 |
| May 5, 2023 | 5.45 | 0.30 | 5.83% | 5.15 | 5.48 | 5.08 |
Sutro Biopharma, Inc. Events
| Tijd (UTC) (UTC) | Land | Evenement |
|---|---|---|
| Wednesday, June 7, 2023 | ||
| Tijd (UTC) (UTC) 20:30 | Land US
| Evenement Sutro Biopharma Inc at Jefferies Healthcare Conference Sutro Biopharma Inc at Jefferies Healthcare ConferenceForecast -Previous - |
| Thursday, June 8, 2023 | ||
| Tijd (UTC) (UTC) 19:00 | Land US
| Evenement Sutro Biopharma Inc Annual Shareholders Meeting Sutro Biopharma Inc Annual Shareholders MeetingForecast -Previous - |
| Monday, August 7, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q2 2023 Sutro Biopharma Inc Earnings Release Q2 2023 Sutro Biopharma Inc Earnings ReleaseForecast -Previous - |
| Monday, November 6, 2023 | ||
| Tijd (UTC) (UTC) 10:59 | Land US
| Evenement Q3 2023 Sutro Biopharma Inc Earnings Release Q3 2023 Sutro Biopharma Inc Earnings ReleaseForecast -Previous - |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totale inkomsten | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Inkomsten | 67.772 | 61.88 | 42.722 | 42.736 | 38.419 |
| Totale bedrijfskosten | 196.715 | 160.404 | 113.779 | 98.204 | 75.642 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 59.544 | 56.004 | 36.818 | 32.592 | 21.38 |
| Onderzoek & Ontwikkeling | 137.171 | 104.4 | 76.961 | 65.612 | 54.262 |
| Bedrijfsresultaat | -128.943 | -98.524 | -71.057 | -55.468 | -37.223 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | 12.239 | -7.014 | 38.929 | -0.276 | -0.007 |
| Overige, Netto | 1.913 | ||||
| Netto inkomen voor belastingen | -116.704 | -105.538 | -32.128 | -55.744 | -35.317 |
| Netto inkomen na belastingen | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Netto inkomen voor extra. Posten | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Netto inkomen | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Verwaterd Netto Inkomen | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Verwaterd Gewogen Gemiddelde Aandelen | 50.7392 | 46.1191 | 32.5735 | 22.9586 | 22.8482 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Dividends per Share - Common Stock Primary Issue | |||||
| Verwaterde Genormaliseerde Winst per Aandeel | -2.34935 | -2.28838 | -0.98632 | -2.42803 | -1.54572 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totale inkomsten | 12.674 | 8.632 | 25.147 | 28.096 | 5.897 |
| Inkomsten | 12.674 | 8.632 | 25.147 | 28.096 | 5.897 |
| Totale bedrijfskosten | 54.911 | 57.854 | 46.357 | 47.475 | 45.029 |
| Verkoop/Algemeen/Admin. Uitgaven, Totaal | 15.512 | 14.719 | 14.643 | 15.143 | 15.039 |
| Onderzoek & Ontwikkeling | 39.399 | 43.135 | 31.714 | 32.332 | 29.99 |
| Bedrijfsresultaat | -42.237 | -49.222 | -21.21 | -19.379 | -39.132 |
| Renteopbrengsten (-uitgaven), netto Niet-operationeel | -7.418 | 14.628 | 1.722 | -4.133 | 0.022 |
| Netto inkomen voor belastingen | -49.655 | -34.594 | -19.488 | -23.512 | -39.11 |
| Netto inkomen na belastingen | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Netto inkomen voor extra. Posten | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Netto inkomen | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Inkomsten beschikbaar voor gewone aandelen Excl. Extra. Posten | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Inkomsten beschikbaar voor gewone aandelen Incl. Extra. Posten | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Verwaterd Netto Inkomen | -50.05 | -34.594 | -19.488 | -26.012 | -39.11 |
| Verwaterd Gewogen Gemiddelde Aandelen | 58.7234 | 57.09 | 52.3457 | 46.9572 | 46.4996 |
| Verwaterde Winst per Aandeel Exclusief Buitengewone Posten | -0.8523 | -0.60596 | -0.37229 | -0.55395 | -0.84108 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Verwaterde Genormaliseerde Winst per Aandeel | -0.8523 | -0.60596 | -0.37229 | -0.55395 | -0.84108 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 353.153 | 218.515 | 378.182 | 128.568 | 209.946 |
| Geldmiddelen en kortetermijnbeleggingen | 334.364 | 197.938 | 368.137 | 117.864 | 204.492 |
| Geldmiddelen & Equivalenten | 47.254 | 30.414 | 206.152 | 4.96 | 125.298 |
| Korte Termijn Investeringen | 287.11 | 167.524 | 161.985 | 112.904 | 79.194 |
| Totale Vorderingen, Netto | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Accounts Receivable - Trade, Net | 7.122 | 12.454 | 5.559 | 6.298 | 2.489 |
| Prepaid Expenses | 11.667 | 8.123 | 4.486 | 4.406 | 2.965 |
| Total Assets | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Property/Plant/Equipment, Total - Net | 51.064 | 51.591 | 12.935 | 9.633 | 10.934 |
| Property/Plant/Equipment, Total - Gross | 88.969 | 85.017 | 49.762 | 43.481 | 40.23 |
| Accumulated Depreciation, Total | -37.905 | -33.426 | -36.827 | -33.848 | -29.296 |
| Other Long Term Assets, Total | 2.727 | 2.527 | 2.994 | 2.56 | 2.259 |
| Total Current Liabilities | 66.547 | 41.736 | 29.597 | 32.967 | 36.423 |
| Accounts Payable | 4.797 | 11.327 | 5.544 | 5.584 | 3.061 |
| Accrued Expenses | 32.491 | 12.454 | 8.823 | 6.017 | 6.217 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | 12.5 | 9.375 | 0 | 1 | 4.724 |
| Other Current Liabilities, Total | 16.759 | 8.58 | 15.23 | 20.366 | 22.421 |
| Total Liabilities | 189.896 | 88.844 | 62.063 | 58.581 | 91.6 |
| Total Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Long Term Debt | 3.771 | 15.738 | 24.545 | 8.876 | 10 |
| Other Liabilities, Total | 119.578 | 31.37 | 7.921 | 16.738 | 45.177 |
| Total Equity | 217.048 | 252.564 | 332.048 | 97.789 | 131.539 |
| Redeemable Preferred Stock | 0 | 0 | |||
| Common Stock | 0.058 | 0.046 | 0.046 | 0.023 | 0.023 |
| Additional Paid-In Capital | 670.223 | 586.243 | 559.746 | 293.346 | 281.891 |
| Retained Earnings (Accumulated Deficit) | -452.615 | -333.411 | -227.873 | -195.745 | -150.328 |
| Other Equity, Total | -0.618 | -0.314 | 0.129 | 0.165 | -0.047 |
| Total Liabilities & Shareholders’ Equity | 406.944 | 341.408 | 394.111 | 156.37 | 223.139 |
| Total Common Shares Outstanding | 57.4995 | 46.3812 | 45.7521 | 23.099 | 22.8482 |
| Long Term Investments | 0 | 68.775 | 0 | 15.609 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Totaal vlottende activa | 304.063 | 353.153 | 346.553 | 331.511 | 228.742 |
| Geldmiddelen en kortetermijnbeleggingen | 276.494 | 334.364 | 324.248 | 225.636 | 209.145 |
| Geldmiddelen & Equivalenten | 62.472 | 47.254 | 96.779 | 79.115 | 28.901 |
| Korte Termijn Investeringen | 214.022 | 287.11 | 227.469 | 146.521 | 180.244 |
| Totale Vorderingen, Netto | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Accounts Receivable - Trade, Net | 9.873 | 7.122 | 11.241 | 97.671 | 11.686 |
| Prepaid Expenses | 17.696 | 11.667 | 11.064 | 8.204 | 7.911 |
| Total Assets | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Property/Plant/Equipment, Total - Net | 49.831 | 51.064 | 51.354 | 51.316 | 51.657 |
| Long Term Investments | 0 | 0 | 0 | 20.699 | |
| Other Long Term Assets, Total | 4.122 | 2.727 | 2.793 | 2.793 | 2.577 |
| Total Current Liabilities | 59.486 | 66.547 | 58.288 | 44.572 | 38.76 |
| Accounts Payable | 5.058 | 4.797 | 12.443 | 12.567 | 10.705 |
| Accrued Expenses | 24 | 32.491 | 13.011 | 8.868 | 6.486 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 17.186 | 16.759 | 20.334 | 10.637 | 9.069 |
| Total Liabilities | 172.603 | 189.896 | 170.974 | 176.562 | 83.303 |
| Total Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Long Term Debt | 0 | 3.771 | 6.783 | 9.779 | 12.762 |
| Other Liabilities, Total | 113.117 | 119.578 | 105.903 | 122.211 | 31.781 |
| Total Equity | 185.413 | 217.048 | 229.726 | 209.058 | 220.372 |
| Common Stock | 0.06 | 0.058 | 0.055 | 0.049 | 0.047 |
| Additional Paid-In Capital | 688.125 | 670.223 | 649.028 | 608.898 | 593.998 |
| Retained Earnings (Accumulated Deficit) | -502.665 | -452.615 | -418.021 | -398.533 | -372.521 |
| Total Liabilities & Shareholders’ Equity | 358.016 | 406.944 | 400.7 | 385.62 | 303.675 |
| Total Common Shares Outstanding | 60.1618 | 57.4995 | 54.6314 | 48.6742 | 46.3271 |
| Current Port. of LT Debt/Capital Leases | 13.242 | 12.5 | 12.5 | 12.5 | 12.5 |
| Other Equity, Total | -0.107 | -0.618 | -1.336 | -1.356 | -1.152 |
- Jaarlijks
- Per kwartaal
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Netto-inkomen/Beginsaldo | -119.204 | -105.538 | -32.128 | -55.744 | -35.317 |
| Geldmiddelen uit Operationele Activiteiten | 3.549 | -81.679 | -67.802 | -65.023 | 12.683 |
| Geldmiddelen uit Operationele Activiteiten | 5.69 | 4.844 | 4.297 | 4.777 | 4.539 |
| Niet-Geldelijke Posten | 12.658 | 36.635 | -28.485 | 9.208 | 0.855 |
| Contant Betaalde Rente | 1.869 | 2.046 | 1.675 | 1.049 | 1.275 |
| Veranderingen in het Operationeel Kapitaal | 104.405 | -17.62 | -11.486 | -23.264 | 42.606 |
| Geldmiddelen uit Investeringsactiviteiten | -35.022 | -97.315 | 0.604 | -51.131 | -80.19 |
| Kapitaaluitgaven | -7.858 | -15.323 | -7.129 | -3.481 | -1.557 |
| Overige Cash Flow investeringsposten, Totaal | -27.164 | -81.992 | 7.733 | -47.65 | -78.633 |
| Geldmiddelen uit Financieringsactiviteiten | 48.313 | 3.256 | 269.247 | -4.184 | 170.785 |
| Financiering van Cash Flow Posten | -0.463 | 0.778 | -0.314 | 0.636 | 1.208 |
| Uitgifte (Aflossing) van aandelen, netto | 58.151 | 2.478 | 254.561 | 0.18 | 169.577 |
| Nettowijziging in Geldmiddelen | 16.84 | -175.738 | 202.049 | -120.338 | 103.278 |
| Uitgifte (Aflossing) van Schulden, Netto | -9.375 | 0 | 15 | -5 | |
| Cash Taxes Paid | 0 | 0.103 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -50.05 | -119.204 | -84.61 | -65.122 | -39.11 |
| Cash From Operating Activities | -60.991 | 3.549 | 27.413 | -38.441 | -35.255 |
| Cash From Operating Activities | 1.615 | 5.69 | 4.162 | 2.724 | 1.327 |
| Non-Cash Items | 11.855 | 12.658 | 23.021 | 19.094 | 7.751 |
| Cash Interest Paid | 0.00039 | 1.869 | 1.442 | 0.998 | 0.504 |
| Changes in Working Capital | -24.411 | 104.405 | 84.84 | 4.863 | -5.223 |
| Cash From Investing Activities | 67.451 | -35.022 | 2.86 | 80.897 | 32.982 |
| Capital Expenditures | -0.942 | -7.858 | -4.491 | -3.753 | -1.553 |
| Other Investing Cash Flow Items, Total | 68.393 | -27.164 | 7.351 | 84.65 | 34.535 |
| Cash From Financing Activities | 8.758 | 48.313 | 36.092 | 6.245 | 0.76 |
| Financing Cash Flow Items | -0.451 | -0.463 | -0.463 | -0.413 | -0.426 |
| Issuance (Retirement) of Stock, Net | 12.334 | 58.151 | 42.805 | 9.783 | 1.186 |
| Issuance (Retirement) of Debt, Net | -3.125 | -9.375 | -6.25 | -3.125 | 0 |
| Net Change in Cash | 15.218 | 16.84 | 66.365 | 48.701 | -1.513 |
| Naam investeerder | Type investeerder | Percentage uitstaand | Aandelen in bezit | Wijziging aandelen | Datum bezit | Omzetcijfer |
|---|---|---|---|---|---|---|
| Suvretta Capital Management, LLC | Hedge Fund | 9.4164 | 5689086 | 123987 | 2023-03-31 | LOW |
| Rubric Capital Management LP | Hedge Fund | 7.2173 | 4360487 | 1148615 | 2023-03-31 | MED |
| BlackRock Institutional Trust Company, N.A. | Investment Advisor | 6.5001 | 3927145 | 25108 | 2023-03-31 | LOW |
| BVF Partners L.P. | Hedge Fund | 5.5414 | 3347946 | 0 | 2023-03-31 | LOW |
| State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 4.8376 | 2922712 | 1071427 | 2023-03-31 | LOW |
| Franklin Advisers, Inc. | Investment Advisor/Hedge Fund | 4.6602 | 2815577 | -229 | 2023-03-31 | LOW |
| The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 4.5963 | 2776962 | 132290 | 2023-03-31 | LOW |
| Holocene Advisors, LP | Hedge Fund | 3.5303 | 2132873 | -180669 | 2023-03-31 | HIGH |
| Baillie Gifford & Co. | Investment Advisor | 3.0913 | 1867654 | -961 | 2023-03-31 | LOW |
| Candriam Belgium S.A. | Investment Advisor/Hedge Fund | 3.0799 | 1860775 | 1071591 | 2023-03-31 | LOW |
| Frazier Healthcare Partners | Venture Capital | 2.9404 | 1776479 | 0 | 2023-03-31 | LOW |
| Samsara BioCapital, LLC | Venture Capital | 2.7734 | 1675579 | 0 | 2023-03-31 | LOW |
| Candriam Luxembourg S.A. | Investment Advisor | 2.6949 | 1628181 | -60000 | 2023-04-30 | HIGH |
| Dimensional Fund Advisors, L.P. | Investment Advisor/Hedge Fund | 1.9418 | 1173199 | 505656 | 2023-03-31 | LOW |
| Verition Fund Management LLC | Hedge Fund | 1.8965 | 1145786 | -458443 | 2023-03-31 | HIGH |
| Parkman Healthcare Partners LLC | Hedge Fund | 1.8207 | 1100038 | 234063 | 2023-03-31 | HIGH |
| Goldman Sachs Asset Management, L.P. | Investment Advisor | 1.7942 | 1084017 | 159429 | 2023-03-31 | LOW |
| Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.7484 | 1056314 | 35235 | 2023-03-31 | LOW |
| Kynam Capital Management LP | Hedge Fund | 1.4927 | 901836 | 497292 | 2023-03-31 | HIGH |
| Millennium Management LLC | Hedge Fund | 1.4758 | 891616 | -477405 | 2023-03-31 | HIGH |
Waarom Capital.com? De cijfers spreken voor zichzelf.
Capital.com Group535K+
Handelaren
87K+
Actieve klanten per maand
$113M+
Maandelijks beleggingsvolume
$64M+
Opgenomen per maand
Handelscalculator
Bereken uw virtuele winst- en verliesrekening indien u een CFD-positie had geopend op een bepaalde datum (kies een datum) en gesloten op een andere datum (kies een datum).
Handelscommissie
0
- 1:1
Hefboom
1:1
- 20
- 100
- 500
- 1000
- 10000
Investering
Positiegrootte (hefboomwerking x investering):
Openingskoers
Slotkoers
Short Long
Sutro Biopharma, Inc. Company profile
Over Sutro Biopharma, Inc.
Sutro Biopharma, Inc. is een bedrijf dat geneesmiddelen ontdekt, ontwikkelt en produceert in een klinische fase. Het richt zich op het inzetten van zijn geïntegreerde celvrije eiwitsynthese en plaatsspecifiek conjugatieplatform, XpressCF, om een verscheidenheid aan eiwithoudende therapeutica te creëren, in eerste instantie voor kanker. Het houdt zich bezig met het ontwerpen van therapeutica die krachtige modaliteiten gebruiken, waaronder cytokine-gebaseerde therapeutica, immuno-oncologische middelen, antilichaam-drug conjugaten (ADC's) en bispecifieke antilichamen die gericht zijn tegen klinisch gevalideerde doelwitten. De productkandidaat omvat STRO-002 en STRO-001. STRO-002 is een ADC gericht tegen folaatreceptor-alfa, voor patiënten met FolRα-expresserende kankers, zoals eierstok- en endometriumkankers. STRO-001, is een ADC gericht tegen CD74, voor patiënten met B-cel maligniteiten, zoals multipel myeloom en non-Hodgkin lymfoom. Zijn kandidaat-producten worden ontworpen en geoptimaliseerd voor therapeutische index door het plaatsen van linker-koppen op specifieke plaatsen binnen het antilichaam.
| Industry: | Bio Therapeutic Drugs |
111 Oyster Point Blvd.
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Winst- en verliesrekening
- Annual
- Quarterly
Mensen bekijken ook
Nog steeds op zoek naar een broker die u kunt vertrouwen?
Sluit u aan bij de 535.000+ handelaren die er wereldwijd voor kozen om met Capital.com te handelen